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criteria included acute or recent myocardial infarction (MI), left ventricular ejection
fraction 30%, left main or ostial location, major bifurcation disease, chronic total
occlusion, and target vessel thrombus. Routine angiographic follow-up was not per-
formed. Planned clinical follow-up is at 1, 6, 12, and 18 months, and annually to 5 years.
Results: Patients were predominantly male (62.7%), and 30.0% presented with medically
treated diabetes. At baseline, target lesion length was 24.388.21mm and reference vessel
diameter was 2.560.40mm. The study met its primary endpoint of 12-month target
lesion failure (composite of target vessel related cardiac death/MI and ischemia-driven
target lesion revascularization) with a rate of 3.2%, which was not significantly different
(p0.001) than a prespecified performance goal of 19.4% (based on historical outcomes
with 32mm paclitaxel-eluting stents, the only long drug-eluting stent approved in the US
when PLATINUM LL was initiated). At 1-year follow-up, there were 3 instances of target
lesion revascularization (3.1%), 1 non-cardiac death, and no cardiac deaths, MIs, or stent
thromboses. Two-year clinical follow-up will be reported.
Conclusions: The 1-year results of the PLATINUM LL study support the use of the
PROMUS Element 32mm and 38mm stents in the treatment of long coronary lesions.
Two-year results will be available for presentation for the first time at TCT in October
2012.
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Background: A drug-eluting stent consists of 3 components of equal importance: a
metallic platform, a polymer and a drug, all influencing acute and long term results both
in safety and efficacy. The Platinum plus trial was designed to compare the Promus
element stent to the Xience Prime. These stents have the same polymer poly (n butyl
methacrylate) (PBMA) and poly (vinylidene fluoride co hexafluoropropylene) (PVDF-
HFP)] and drug (Everolimus) but different platforms (platinum-chromium for the Promus
element, cobalt chromium for the Xience prime) and distinct stent designs.
Methods: Methods. The trial was designed as a non-inferiority single blind randomized
2:1 trial (Promus G1/XienceG2 that recruited 2985 consecutive, all-comer patients in 48
European centers. The primary endpoint was TVF at 1 year.
Results: Results. Population consisted of 79% of males, mean age: 65 yrs  9 yrs.
Indications were 42 % stable angina 31.2% ACS and 10.2 % silent ischemia. Risk factors
were well balanced between the 2 populations as follows: hypertension (65.8% vs. 68.1%,
hypercholesterolemia (66.08% vs. 65.5%), diabetes I (3.5% vs. 4.07%), diabetes II (24.8
% vs. 22.4%), insulin-treated diabetes (7.4% vs. 6.8%), family history (32.4% vs. 23.3%),
current smoker (20.4% vs. 19.9%). Procedural success was 98.4% in recipients of Promus
stents and 97.8 % for Xience prime. Mean number of stents implanted per patient was 1.7
0.8. In-hospital complications included death N3 and N1 (0.15 % and 0.10 %) for
Promus and Xience, respectively, MI N7 (0.36%) and N2 (0.19%), emergency
CABG N1 and N0 (0.05% and 0 %), repeat PCI (N4, N1). The observed
differences were statistically not significant.
Conclusions: Conclusion: No differences in acute results were observed between the 2
stents; the 30-day outcome will be available for the meeting.
TCT-614
Remote ischemic preconditioning improves outcome out to 6-years following
elective percutaneous coronary intervention: the CRISP-Stent trial.
Stephen Hoole1, William Watson1, Adam Brown1, William Davies1, David Dutka2
1Papworth Hospital, Cambridge, United Kingdom, 2Addenbrooke’s Hospital,
Cambridge, United Kingdom
Background: Remote ischemic preconditioning (rIPC) attenuates MI4a in humans
undergoing elective percutaneous coronary intervention (PCI). However the long-term
impact of rIPC on clinical outcomes after PCI is unknown. We hypothesized that rIPC
attenuation of MI4a would improve clinical outcome at 6-years.
Methods: We randomized 215 patients with normal cardiac troponin-I (cTnI 
0.04ng/mL), undergoing elective PCI to either rIPC (n  110): three 5-minute blood
pressure cuff inflations to 200mmHg around the upper arm with 5-minutes of cuff
deflation between, or control (n  105): a deflated cuff throughout, before PCI. Patients
taking nicorandil or glibenclamide were excluded and randomization was stratified for
diabetes mellitus (DM). Post-PCI serum cardiac troponin-I (cTnI) levels were recorded at
24-hours and major adverse cardiac and cerebral event (MACCE) rate determined at
6-years (90% follow-up, mean time to event or last follow-up: 1579.7 	/ 603.6 days).
Results: The two groups were matched demographically. Median 24-hour cTnI was
significantly lower in the rIPC group (0.06 vs. 0.16ng/mL, p0.04). Mean cTnI was
higher in those with MACCE (0.91 vs. 2.07ng/mL, p0.05). MACCE rate at 6-years was
significantly lower in the rIPC group (23 vs. 36, p0.039, Figure). The non-DM subgroup
(n166) MACCE rate at 6-years was significantly lower following rIPC (17 vs. 29,
p0.045) but those with DM (n49) did not derive benefit from rIPC (6 vs. 7, p0.541).
Conclusions: Fewer patients receiving rIPC have post-PCI cTnI release and rIPC has a
superior MACCE-free survival compared to control out to 6-years.
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Background: Although the use of drug-eluting stents (DES) appears to markedly reduce
restenosis in patients undergoing percutaneous coronary interventions (PCI), there are
ongoing discussions with regards to late and very late stent thrombosis (LST and VLST).
Some reports have indicated that coarse irregularities of DES coating could play a role in
promoting stent thrombosis. The aim of this study was to investigate whether and where
damage to surface of DES occurs when the DES was delivered through a newly deployed
stent.
Methods: Fifteen coronary artery phantom models were constructed with a tube of
approximately 3 mm inner diameter. Fifteen Paclitaxel-eluting stents (PES) were
implanted in each curved tube (r20 mm). Then, the other 15 PES were delivered to pass
through the implanted stents with guide wire, and moved back and forth completely
through them three times. The entire accessible surface area of these unexpanded and
expanded stents was examined with a scanning electron microscope. Each PES was
divided into 4 equivalent parts for qualitative assessment with/without damage of
polymer. We named the most distal part as part 1 (P1) and the most proximal part as part
4 (P4), respectively.
Results: Damage was observed more frequently in distal part than in proximal part of
both expanded and unexpanded stents (as shown in figures).
Conclusions: Placement of DES through an expanded stent could cause damage to
polymer of DES. In such cases, the distal site of DES might be easy to fail to prevent
restenosis and easy to occur LST and VLST.
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